title: Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality.
abstract: OBJECTIVE
  To evaluate the effectiveness of a well-controlled programme of early detection and treatment of prostate cancer in the population of Tyrol, Austria, where such a programme of early detection and treatment was initiated in 1988 and where prostate-specific antigen (PSA) testing was offered for free to all men aged 45-75 years from 1993.
  
  
  METHODS
  Comparison of prostate cancer mortality rates in Tyrol and the rest of Austria was accomplished through a generalized additive model. A piecewise linear change-point Poisson regression model was used to compare mortality rates in Tyrol and the rest of Austria. Standardized mortality ratios were calculated with reference to the mortality rates in 1986-1990.
  
  
  RESULTS
  In all, 86.6% of eligible men have been tested at least once since 1993. Cancer deaths in Tyrol in 2005 were 54% (95% confidence interval [CI] 34-69%) lower than expected compared with 29% (95% CI 22-35%) in the rest of Austria. The decreasing trend in prostate cancer mortality was significantly greater in Tyrol compared with the rest of Austria (P = 0.001). A significant migration to lower stage disease occurred and radical prostatectomy was associated with low morbidity.
  
  
  CONCLUSIONS
  In the Tyrol region where treatment is freely available to all patients, where widespread PSA testing and treatment with curative intent occurs, there was a reduction in prostate cancer mortality rates which was significantly greater than the reduction in the rest of Austria. This reduction in prostate cancer mortality is most probably due to early detection, consequent down-staging and effective treatment of prostate cancer.
authors.affiliation: Department of Urology, University of Innsbruck, Innsbruck, Austria. georg.bartsch@uibk.ac.at
authors.forename: Georg
authors.initials: G
authors.lastname: Bartsch
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Horninger
authors.forename: Helmut
authors.initials: H
authors.lastname: Klocker
authors.forename: Alexandre
authors.initials: A
authors.lastname: Pelzer
authors.forename: Jasmin
authors.initials: J
authors.lastname: Bektic
authors.forename: Wilhelm
authors.initials: W
authors.lastname: Oberaigner
authors.forename: Harald
authors.initials: H
authors.lastname: Schennach
authors.forename: Georg
authors.initials: G
authors.lastname: Schäfer
authors.forename: Ferdinand
authors.initials: F
authors.lastname: Frauscher
authors.forename: Mathieu
authors.initials: M
authors.lastname: Boniol
authors.forename: Gianluca
authors.initials: G
authors.lastname: Severi
authors.forename: Chris
authors.initials: C
authors.lastname: Robertson
authors.forename: Peter
authors.initials: P
authors.lastname: Boyle
mesh_terms: D000328:Adult; D000368:Aged; D001317:Austria / Q000453:epidemiology; D001706:Biopsy / Q000706:statistics & numerical data; D042241:Early Diagnosis; D004812:Epidemiologic Methods; D006801:Humans; D008297:Male; D008875:Middle Aged; D011467:Prostate / Q000473:pathology*; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy; D011788:Quality of Life; D016896:Treatment Outcome
chemical_list: D017430:Prostate-Specific Antigen